EAACI Congress 2024

Back
31 May - 03 June 2024 Valencia, Spain

Challenges in Biologics for Chronic Rhinosinusitis with Nasal Polyps

Sunday 02 Jun, 16:45 PM - 18:15 PM Valencia, Spain
Granada Oral Abstract Sessions
16:45
Effectiveness and Safety of Dupilumab in patients with chronic rhinosinusitis with nasal polyps After One Year of Therapy: Results from a real-world non-interventional study in Germany (ProGNOSE)
16:57
Mepolizumab significantly reduces clinical interventions in the management of patients with CRSwNP: post hoc analysis of SYNAPSE using a composite endpoint
17:09
Initiation of dupilumab led to reduced use of corticosteroids and antibiotics over 12 months in patients with chronic rhinosinusitis with nasal polyps treated in US real world practice
17:21
Dupilumab treatment effectively reduces nasal type 2 cytokine production following acetylsalicylic acid provocation in N-ERD patients
17:33
Comparative Gene Expression Analysis in Blood Samples and Nasal Polyps during Dupilumab Treatment for CRSwNP
17:45
Modulation of eosinophilic and neutrophilic inflammation in patients with chronic rhinosinusitis with nasal polyps treated with dupilumab, assessed by nasal cytology and biopsy histology
17:57
The effect of therapies targeting Type 2 inflammation on Neutrophil Extracellular Traps (NETs) and Extracellular Eosinophilic Traps (EETs) in severe CRSwNP

Speakers